Teduglutide, an analog of the endogenous hormone glucagon-like peptide-2, is currently being developed for the treatment of short bowel syndrome.
Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. I
We investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function in patients with T2DM insufficiently controlled on metformin monotherapy during a hyperglycaemic clamp investigation.
Basal insulin peglispro (BIL) has a peripheral-to-hepatic distribution of action that resembles endogenous insulin and a prolonged duration of action with a flat pharmacokinetic/pharmacodynamic profile at steady …
First published in Journal Diabetes care on 2017 JanDiabetes Care. 2017 Jan;40(1):63-68. doi: 10.2337/dc16-1525. Epub 2016 Nov 4
Read Article
First published in Endocrine. 2017 Apr/ Endocrine. 2017 Apr56(1):158-163. doi: 10.1007/s12020-016-1179-z. Epub 2016 Nov 30
Read Article
First published in John Wiley & Sons Ltd., Diabetes obesity and metabolism on 2017 Apr.Diabetes Obes Metab. 2017 Apr;19(4):489-495. doi:...
Read Article
First published in Journal of Diabetes Science and Technology on 2018 JanJ Diabetes Sci Technol. 2018 Jan;12(1):163-168. doi: 10.1177/1932296817735121. Epub...
Read Article
First published in Journal of Diabetes Science and Technology on 2018 MayJ Diabetes Sci Technol. 2018 Jan;12(1):163-168. doi: 10.1177/1932296817735121. Epub...
Read Article
First published in Der Internist on 2017 MarsInternist (Berl). 2017 Mar;58(3):293-302. doi: 10.1007/s00108-017-0189-0. Review. German
Read Article